63. J Allergy Clin Immunol Glob. 2024 Sep 634100339. doi 10.1016j.jacig.2024.100339. eCollection 2024 Nov. Case report of secondary Tcell deficiency following the AstraZeneca COVID19 vaccine. Esmailian A1, Barnes SL123, Pumar M3. Author information 1Faculty of Medicine, Monash University, Melbourne, Australia. 2Monash Lung Sleep Allergy and Immunology, Clayton, Australia. 3Monash Health, Clayton, Australia. We present a case of secondary Tcell deficiency particularly affecting CD4 T cells, along with the emergence of chronic spontaneous urticaria in a patient following COVID19 vaccination. The condition was partially managed with omalizumab after initial firstline therapy proved ineffective. 2024 The Authors. DOI 10.1016j.jacig.2024.100339 PMCID PMC11459643 PMID 39380982 Conflict of interest statement Disclosure of potential conflict of interest The authors declare that they have no relevant conflicts of interest.